WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on January 29, 2021 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 3, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 1, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 1, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on May 28, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 29, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 30, 2021 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2020 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 2, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on October 30, 2020 the compensation committee of the Company’s Board of Directors granted a
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 1, 2020-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 30, 2020 the compensation committee of the Company’s Board of Directors granted